[1]孙立平,李晶华,洪彩玲,等.非酒精性脂肪性肝病的进展性肝纤维化影响因素分析[J].医学信息,2021,34(10):104-106.[doi:10.3969/j.issn.1006-1959.2021.10.028]
　SUN Li-ping,LI Jing-hua,HONG Cai-ling,et al.Analysis of Influencing Factors of Progressive Liver Fibrosis in Non-alcoholic Fatty Liver Disease[J].Medical Information,2021,34(10):104-106.[doi:10.3969/j.issn.1006-1959.2021.10.028]
点击复制

非酒精性脂肪性肝病的进展性肝纤维化影响因素分析()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年10期
页码:
104-106
栏目:
论著
出版日期:
2021-05-15

文章信息/Info

Title:
Analysis of Influencing Factors of Progressive Liver Fibrosis in Non-alcoholic Fatty Liver Disease
文章编号:
1006-1959（2021）10-0104-03
作者:
孙立平; 李晶华; 洪彩玲; 等
（首都医科大学密云教学医院感染性疾病科，北京 101500）
Author(s):
SUN Li-ping; LI Jing-hua; HONG Cai-ling; et al.
(Department of Infectious Diseases,Miyun Teaching Hospital,Capital Medical University,Beijing 101500,China)
关键词:
非酒精性脂肪性肝病; 进展性肝纤维化; NAFLD纤维化评分
Keywords:
Non-alcoholic fatty liver disease; Progressive liver fibrosis; NAFLD fibrosis score
分类号:
R575
DOI:
10.3969/j.issn.1006-1959.2021.10.028
文献标志码:
A
摘要:
目的 分析非酒精性脂肪性肝病(NAFLD)的进展性纤维化影响因素。方法 选取2019年9月~2020年6月首都医科大学密云教学医院收治的NAFLD患者192例作为研究对象，根据NFS评分结果将NFS积分＞0.676设为进展性纤维化组，-1.455~0.676设为不确定组，＜-1.455设为无纤维化组，分析三组临床资料特征，并采用Logistic多因素回归分析NAFLD进展性纤维化影响因素。结果 进展性纤维化组61例（31.77%），无纤维化组96例（50.00%），不确定组35例（18.23%）。三组BMI、AST/ALT、FBG、腰围、AST、ALB、PLT、HDLC比较，差异有统计学意义（P＜0.05）；三组性别、年龄、ALT、TG、TC、LDLC比较，差异无统计学意义（P＞0.05）。Logistic多因素回归分析显示，腰围（OR=1.149，95%CI：1.025~1.334）、BMI（OR=1.421，95%CI：1.073~1.924）、AST/ALT（OR=1.857，95%CI：1.046~3.454）、HDLC（OR=-0.532，95%CI：0.292~0.994）是NAFLD进展性纤维化的影响因素。结论 腰围、BMI、AST/ALT、HDLC与NAFLD进展性纤维化密切相关，通过监测以上指标，可早期发现并干预NAFLD进展性纤维化，对控制并发症及改善预后具有重要意义。
Abstract:
Objective To analyze the influencing factors of progressive fibrosis in non-alcoholic fatty liver disease (NAFLD).Methods A total of 192 NAFLD patients admitted to the Miyun Teaching Hospital of Capital Medical University from September 2019 to June 2020 were selected as the research objects.According to the results of NFS score, NFS score> 0.676 was set as the progressive fibrosis group, -1.455-0.676 was set as the uncertain group, and <-1.455 was set as the non-fibrosis group.The characteristics of the three groups of clinical data were analyzed, and Logistic multivariate regression was used to analyze the influencing factors of NAFLD progressive fibrosis.Results 61 cases (31.77%) in the progressive fibrosis group, 96 cases (50.00%) in the non-fibrosis group, and 35 cases (18.23%) in the uncertain group. The three groups of BMI, AST/ALT, FBG, waist circumference, AST, ALB, PLT, HDLC were compared,the difference was statistically significant (P<0.05);There was no significant difference in gender, age, ALT, TG, TC, and LDLC among the three groups (P>0.05).Logistic multivariate regression analysis showed that waist circumference (OR=1.149, 95%CI: 1.025-1.334), BMI (OR=1.421, 95%CI: 1.073-1.924), AST/ALT (OR=1.857, 95%CI: 1.046-3.454), HDLC (OR=-0.532, 95%CI: 0.292-0.994) were the influencing factors of NAFLD progressive fibrosis.Conclusion Waist circumference, BMI, AST/ALT, HDLC are closely related to NAFLD progressive fibrosis. By monitoring the above indicators, early detection and diagnosis of NAFLD progressive fibrosis can be intervened, which is of great significance for controlling complications and improving prognosis.

参考文献/References:

[1]田宏扬,鲁晓岚,夏智红.无创评估NAFLD肝纤维化的研究及其与肝细胞癌的相关性[J].胃肠病学和肝病学杂志,2020,29(8):846-851.[2]Zhou JH,Cai JJ,She ZG,et al.Noninvasive evaluation of nonalcoholic fatty liver disease:Current evidence and practice[J].World J Gastroenterol,2019,25(11):1307-1326.[3]魏美林,王倩倩,韩峻峰,等.2型糖尿病患者合并非酒精性脂肪肝及脂肪肝纤维化的危险因素分析[J].中华老年多器官疾病杂志,2014,13(11):805-810.[4]Simon TG,Corey KE,Cannon CP,et al.The nonalcoholic fatty liver disease(NAFLD)fibrosis score,cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe[J].Int J Cardiol,2018(270):245-252.[5]张冉,徐异彩,刘琪,等.超声E成像在非酒精性脂肪性肝病诊断中的应用[J].影像科学与光化学,2020,38(5):828-832.[6]周嘉,谢力俊,黄毅浩,等.2型糖尿病合并非酒精性脂肪肝病患者肝纤维化进展相关危险因素研究[J].广西医科大学学报,2016,33(2):270-275.[7]Castera L,Friedrich-Rust M,Loomba R.Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease[J].Gastroenterology,2019,156(5):1264-1281.e4.[8]宋宇豹,高泽峰,闫志峰,等.羟基喜树碱化疗栓塞联合手术切除治疗肝癌的疗效分析[J].中华普通外科杂志,2019,34(2):118-121.[9]陈孝雪.2型糖尿病合并非酒精性脂肪性肝病肝纤维化的相关分析[D].华中科技大学,2016.[10]Younossi ZM,Henry L,Bush H,et al.Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J].Clin Liver Dis,2018,22(1):1-10.[11]蒋莉,杨贵生,马原驰,等. 非酒精性脂肪性肝病患者血清ALT,AST,ALB与肝纤维化的关系[J]. 标记免疫分析与临床,2020,27(8):92-95,149.[12]Fassio F,Alvarez E,Dominguez N,et al.Natural history of nonalcoholic steatohepatitis:a longitudinal study of repeat liver biopsies[J].Hepatology,2004,40(4):820-826.[13]赵培,霍丽静,谭鹤,等.酒精性脂肪肝和非酒精性脂肪肝血液生化学指标的临床研究[J].中国卫生检验杂志,2017,27(23):3436-3438.

相似文献/References:

[1]龙 颖,李运泽,汤中敏,等.非酒精性脂肪性肝病与血尿酸水平测定及其临床意义[J].医学信息,2018,31(07):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
　LONG Ying,LI Yun-ze,TANG Zhong-min,et al.Determination of Serum Uric Acid Level and its Clinical Significance in Non-alcoholic Fatty Liver Disease[J].Medical Information,2018,31(10):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
[2]崔姗姗,刘 英,江 霞.非酒精性脂肪性肝病与胰岛素抵抗的研究进展[J].医学信息,2022,35(10):66.[doi:10.3969/j.issn.1006-1959.2022.10.016]
　CUI Shan-shan,LIU Ying,JIANG Xia.Research Progress on Non-alcoholic Fatty Liver Disease and Insulin Resistance[J].Medical Information,2022,35(10):66.[doi:10.3969/j.issn.1006-1959.2022.10.016]
[3]冯贺强,张彩红.肠道菌群与非酒精性脂肪肝关系的研究进展[J].医学信息,2018,31(12):47.[doi:10.3969/j.issn.1006-1959.2018.12.015]
　FENG He-qiang,ZHANG Cai-hong.Research Progress on the Relationship between Intestinal Flora and Nonalcoholic Fatty Liver[J].Medical Information,2018,31(10):47.[doi:10.3969/j.issn.1006-1959.2018.12.015]
[4]郑 颖,孙华胜,毛乾国.中医防治非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(15):25.[doi:10.3969/j.issn.1006-1959.2018.15.010]
　ZHENG Ying,SUN Hua-sheng,MAO Qian-guo.Progress in Prevention and Treatment of Nonalcoholic Fatty Liver Disease by TCM[J].Medical Information,2018,31(10):25.[doi:10.3969/j.issn.1006-1959.2018.15.010]
[5]李珊珊,陈少彬,龚先琼.中药单体治疗非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(21):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
　LI Shan-shan,CHEN Shao-bin,GONG Xian-qiong.Advances in Research of Traditional Chinese Medicine Monomer in the Treatment of Non-alcoholic Fatty Liver Disease[J].Medical Information,2018,31(10):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
[6]黄玲玉,孙 东,蒋本君,等.天津市某区域体检人群非酒精性脂肪肝调查分析[J].医学信息,2019,32(04):99.[doi:10.3969/j.issn.1006-1959.2019.04.032]
　HUANG Ling-yu,SUN Dong,JIANG Ben-jun,et al.Investigation and Analysis of Non-alcoholic Fatty Liver Disease in Medical Examination Population in A Certain Area of Tianjin[J].Medical Information,2019,32(10):99.[doi:10.3969/j.issn.1006-1959.2019.04.032]
[7]余 辉,李 岳,郭宝娜.非酒精性脂肪性肝病的治疗研究[J].医学信息,2019,32(14):38.[doi:10.3969/j.issn.1006-1959.2019.14.014]
　YU Hui,LI Yue,GUO Bao-na.Treatment of Non-alcoholic Fatty Liver Disease[J].Medical Information,2019,32(10):38.[doi:10.3969/j.issn.1006-1959.2019.14.014]
[8]王佳欣,毛乾国.慢性乙型肝炎合并非酒精性脂肪性肝病 中医辨治的研究进展[J].医学信息,2019,32(16):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]
　WANG Jia-xin,MAO Qian-guo.Advances in Research on TCM Syndrome Differentiation of Chronic Hepatitis B with Nonalcoholic Fatty Liver Disease[J].Medical Information,2019,32(10):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]
[9]蒋晓倩,梁惠卿,刘垚昱,等.吴耀南运用“浊毒”理论论治非酒精性脂肪性肝病验案举隅[J].医学信息,2020,33(04):158.[doi:10.3969/j.issn.1006-1959.2020.04.052]
[10]蔡秀媛,吴春城,梁惠卿,等.非酒精性脂肪性肝病中医证型与客观指标的相关性[J].医学信息,2020,33(09):21.[doi:10.3969/j.issn.1006-1959.2020.09.008]
　CAI Xiu-yuan,WU Chun-cheng,LIANG Hui-qing,et al.Correlation Between TCM Syndromes of Nonalcoholic Fatty Liver Disease and Objective Indexes[J].Medical Information,2020,33(10):21.[doi:10.3969/j.issn.1006-1959.2020.09.008]

更新日期/Last Update: 1900-01-01